Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Treatment Options for Severe Refractory Gout When Pegloticase Fails

Diana M. Girnita, MD, PhD, Cody Lee, MD, & Christine Chhakchhuak, MD  |  Issue: August 2016  |  August 12, 2016

Laboratory analysis revealed an elevated creatinine to 1.7 and PUA of 9.6 mg/dL.

Hand X-rays from three years prior were notable for severe polyarticular erosive disease. Plain films obtained in our institution confirmed multiple erosions involving the MCP, DIP and PIP joints, overlying soft tissue masses containing amorphous calcifications, loss of cartilage in the intercarpal bones, and carpal bony erosions. Plain films of the elbows and ankles similarly revealed large amorphous deposits and calcifications. Multiple erosions were also present at the first metatarsal head, tarsometatarsal joints and at the bases of the metatarsal and intertarsal joints.

TABLE 1: Known Genes Associated with Hyperuricemia

(click for larger image)
Table 1:
Known Genes Associated with Hyperuricemia

At that time, treatment with febuxostat was initiated at 40 mg/day, which was gradually increased to 120 mg/day with limited results. Initially, the patient noted a slight improvement in the frequency of his gout flares, but soon he began having recurrent flares, as before. He started to require frequent prednisone bursts and, ultimately, ended up using low-dose prednisone as prophylaxis. His PUA was monitored every three months during this period, and he remained in the range of 9–10 mg/dL.

Given his treatment failure with febuxostat, the decision was made to start pegloticase. Prior to initiating this treatment, a new set of plain films was obtained, which showed progression of tophi, as well as new erosions in multiple sites involving his hands, elbows, feet and ankles.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pegloticase was administered intravenously at 8 mg every two weeks for a total of 10 infusions. In addition, he was treated with 20 mg of prednisone daily because he continued to have acute gout flare-ups on lower doses of prednisone. PUA was checked before each infusion, and the values are reported in Figure 1. After a few infusions, based on the reported PUA values, we discussed with the patient the possibility of discontinuing the infusion due to fear of an infusion reaction from antibody formation. The patient, however, accepted the risks and decided to continue the infusion.

Over the course of his five months of infusions, he subjectively reported improvement in his range of motion, as well as a decrease in the size of his tophi. However, clinically these findings were not appreciated. And although the frequency of gout flares was reduced, this was likely secondary to the prednisone more than the pegloticase itself. Unfortunately, with the exception of one value of 8.1 mg/dL at the time of the second infusion, PUA values remained elevated in his pretreatment range of 9–10 mg/dL. Overall, the infusions were well tolerated, and no hypersensitivity reactions occurred; however, we were unable to check if the patient developed antibodies against pegloticase.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:ClinicalGoutoutcomepegloticaseResearchrheumatologistrheumatologyTreatment

Related Articles

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Prokopenko Oleg / shutterstock.com

    Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout

    January 10, 2022

    A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (metho­trexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout

    October 11, 2016

    We read the case report by Dr. Diana Girnita and colleagues (“Severe Refractory Gout: What options are left when pegloticase fails?” The Rheumatologist, August 2016) with interest. A case is reported of a subject with 20 years of chronic refractory gout who failed to respond to pegloticase therapy, and the potential roles of anti-drug antibodies or…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences